尼泊尔免费药品目录的设计:技术优势与政策进程之间的平衡。

IF 1.7
MDM policy & practice Pub Date : 2017-02-01 eCollection Date: 2017-01-01 DOI:10.1177/2381468317691766
Devika Singh, Alia Cynthia Gonzales Luz, Waranya Rattanavipapong, Yot Teerawattananon
{"title":"尼泊尔免费药品目录的设计:技术优势与政策进程之间的平衡。","authors":"Devika Singh,&nbsp;Alia Cynthia Gonzales Luz,&nbsp;Waranya Rattanavipapong,&nbsp;Yot Teerawattananon","doi":"10.1177/2381468317691766","DOIUrl":null,"url":null,"abstract":"<p><p>As more countries provide free health care, pharmaceutical reimbursement lists are becoming a concern, especially in low- and middle-income countries. In 2007, Nepal decreed that health is a human right and began basic health coverage for a target group of the poor, destitute, elderly, and disabled. The Ministry of Health and Population (MoHP) also provided 40 drugs without cost to all citizens through the Free Drugs List (FDL) program. The FDL was later expanded from 40 to 70 drugs; however, the process of review and update remains unclear. To propose a mechanism for future development of the FDL, we conducted a document review and in-depth consultations with representatives from the MoHP and the World Health Organization Country Office during a workshop in Kathmandu. The FDL suffers from lack of an appropriate process, gaps between the listed drugs and Nepal's burden of disease, and no consideration of the unit costs or cost-effectiveness of drugs included in the list. We propose a new drug selection process that is a variant of the health technology assessment process. This process can be applied not only in Nepal but also in other resource-limited countries that wish to ensure their citizens' access to essential medicines through a pharmaceutical reimbursement list.</p>","PeriodicalId":520707,"journal":{"name":"MDM policy & practice","volume":" ","pages":"2381468317691766"},"PeriodicalIF":1.7000,"publicationDate":"2017-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2381468317691766","citationCount":"6","resultStr":"{\"title\":\"Designing the Free Drugs List in Nepal: A Balancing Act Between Technical Strengths and Policy Processes.\",\"authors\":\"Devika Singh,&nbsp;Alia Cynthia Gonzales Luz,&nbsp;Waranya Rattanavipapong,&nbsp;Yot Teerawattananon\",\"doi\":\"10.1177/2381468317691766\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>As more countries provide free health care, pharmaceutical reimbursement lists are becoming a concern, especially in low- and middle-income countries. In 2007, Nepal decreed that health is a human right and began basic health coverage for a target group of the poor, destitute, elderly, and disabled. The Ministry of Health and Population (MoHP) also provided 40 drugs without cost to all citizens through the Free Drugs List (FDL) program. The FDL was later expanded from 40 to 70 drugs; however, the process of review and update remains unclear. To propose a mechanism for future development of the FDL, we conducted a document review and in-depth consultations with representatives from the MoHP and the World Health Organization Country Office during a workshop in Kathmandu. The FDL suffers from lack of an appropriate process, gaps between the listed drugs and Nepal's burden of disease, and no consideration of the unit costs or cost-effectiveness of drugs included in the list. We propose a new drug selection process that is a variant of the health technology assessment process. This process can be applied not only in Nepal but also in other resource-limited countries that wish to ensure their citizens' access to essential medicines through a pharmaceutical reimbursement list.</p>\",\"PeriodicalId\":520707,\"journal\":{\"name\":\"MDM policy & practice\",\"volume\":\" \",\"pages\":\"2381468317691766\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2017-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/2381468317691766\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MDM policy & practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2381468317691766\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MDM policy & practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2381468317691766","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

摘要

随着越来越多的国家提供免费保健,药品报销清单正成为一个令人关切的问题,特别是在低收入和中等收入国家。2007年,尼泊尔颁布法令,规定健康是一项人权,并开始为穷人、赤贫者、老年人和残疾人等目标群体提供基本医疗保险。卫生和人口部还通过免费药物清单方案向所有公民免费提供40种药物。FDL后来从40种药物扩大到70种;然而,审查和更新的过程仍不清楚。在加德满都的一个讲习班上,我们与卫生部和世界卫生组织国家办事处的代表进行了文件审查和深入磋商,以提出一种未来发展FDL的机制。FDL缺乏适当的程序,所列药物与尼泊尔的疾病负担之间存在差距,而且没有考虑清单所列药物的单位成本或成本效益。我们提出了一种新的药物选择过程,它是卫生技术评估过程的一种变体。这一进程不仅可以应用于尼泊尔,也可以应用于其他资源有限的国家,这些国家希望通过药品报销清单确保其公民获得基本药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Designing the Free Drugs List in Nepal: A Balancing Act Between Technical Strengths and Policy Processes.

Designing the Free Drugs List in Nepal: A Balancing Act Between Technical Strengths and Policy Processes.

Designing the Free Drugs List in Nepal: A Balancing Act Between Technical Strengths and Policy Processes.

Designing the Free Drugs List in Nepal: A Balancing Act Between Technical Strengths and Policy Processes.

As more countries provide free health care, pharmaceutical reimbursement lists are becoming a concern, especially in low- and middle-income countries. In 2007, Nepal decreed that health is a human right and began basic health coverage for a target group of the poor, destitute, elderly, and disabled. The Ministry of Health and Population (MoHP) also provided 40 drugs without cost to all citizens through the Free Drugs List (FDL) program. The FDL was later expanded from 40 to 70 drugs; however, the process of review and update remains unclear. To propose a mechanism for future development of the FDL, we conducted a document review and in-depth consultations with representatives from the MoHP and the World Health Organization Country Office during a workshop in Kathmandu. The FDL suffers from lack of an appropriate process, gaps between the listed drugs and Nepal's burden of disease, and no consideration of the unit costs or cost-effectiveness of drugs included in the list. We propose a new drug selection process that is a variant of the health technology assessment process. This process can be applied not only in Nepal but also in other resource-limited countries that wish to ensure their citizens' access to essential medicines through a pharmaceutical reimbursement list.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信